



## SHORT CURRICULUM VITAE

**Shilpa Chokshi, PhD**

Institute of Hepatology, Foundation for Liver Research

[s.chokshi@researchinliver.org.uk](mailto:s.chokshi@researchinliver.org.uk)

+44 (0) 207 255 9845

### **Brief professional History:**

June 2016-present	Chief Scientific Officer, Foundation for Liver Research Honorary Senior Lecturer, King's College London University
2015-2016	Principal Scientist, Foundation for Liver Research Honorary Senior Lecturer, King's College London University
2010- 2016	Head of Viral Hepatitis/Alcohol Group, Institute of Hepatology Honorary Senior Lecturer, University College London Senior Research Fellow, Birkbeck College, University of London

### **Research Interests:**

My research interests have largely focused on understanding the host response to viral and toxic liver injury in order to develop therapeutic strategies to restore the host immunity and defense.

### **Grants and funding (selected)**

- Research Grant (PI). 2011. Polkemmet Trust. Mitochondrial Dysfunction during alcohol-induced liver injury. £80,000.
- Research Grant (PI). 2012. Bristol Myers-Squibb. Immune responses in patients treated with Interferon-lambda. £385,686.
- Research Grant (PI). 2013-2018. Bristol Myers-Squibb. Immune responses in patients treated with Nivolumab. £920,000.
- Research Grant (Co-PI). 2014. Innovate UK. Technical and Commercial Feasibility of a blood test for prediction of response to interferon treatment in Chronic Hepatitis B patients. GBP 15'000.
- PhD studentship (Co-PI). 2014-2018. Plymouth University. Correlates of immune protection to HCV infection in exposed uninfected intravenous drug abusers. GBP 35'000.
- Research Grant (Co-PI). 2016. NIHR-EME. Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance(NUC-B). £3 million.

### **Selected recent publications**

1. Riva A, Patel V, Kurioka A, Jeffery HC, Wright G, Tarff S, Shawcross D, Ryan J, Evans A, Azarian S, Bajaj J, Fagan A, Patel V, Mehta K, Lopez C, Simonova M, Katzarov K, Hadzhiolova T, Pavlova S, Wendon J, Oo5 YH, Klenerman P, Williams R, **Chokshi S.** Mucosa-associated invariant T-cells link intestinal immunity with antibacterial immune defects in Alcoholic Liver Disease. Gut. 2017 Sept (In Press).
2. Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knecht R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, **Chokshi S.**

- Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. *Front Immunol.* 2017 May 29;8:621.
3. Chokshi S. 'Alcoholic liver disease: Why research is vital'. Adjacent Government Communications March 2017
  4. Hull DN, Cooksley H, **Chokshi S**, Williams RO, Abraham S, Taylor PC. Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. *Arthritis Res Ther.* 2016 Dec 23;18(1):303
  5. Coombes JD, Choi SS, Swiderska-Syn M, Manka P, Reid DT, Palma E, Briones-Orta MA, Xie G, Younis R, Kitamura N, Della Peruta M, Bitencourt S, Dollé L, Oo YH, Mi Z, Kuo PC, Williams R, **Chokshi S**, Canbay A, Claridge LC, Eksteen B, Diehl AM, Syn WK. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. *Biochim Biophys Acta.* 2016 Jan;1862(1):135-44.
  6. Manakkat Vijay GK, Ryan JM, Abeles RD, Ramage S, Patel V, Bernsmeier C, Riva A, McPhail MJ, Tranah TH, Markwick LJ, Taylor NJ, Bernal W, Auzinger G, Willars C, **Chokshi S**, Wendon JA, Ma Y, Shawcross DL. Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure. *Crit Care Med.* 2016 Jan;44(1):43-53.
  7. Podrini C, Koffas A, **Chokshi S**, Vinciguerra M, Lelliott CJ, White JK, Adissu HA, Williams R, Greco A. MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis. *FASEB J.* 2015 May;29(5):1676-87.
  8. Coombes JD, Swiderska-Syn M, Dollé L, Reid D, Eksteen B, Claridge L, Briones-Orta MA, Shetty S, Oo YH, Riva A, **Chokshi S**, Papa S, Mi Z, Kuo PC, Williams R, Canbay A, Adams DH, Diehl AM, van Grunsven LA, Choi SS, Syn WK. Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. *Gut.* 2015 Jul;64(7):1120-31
  9. Markwick LJ, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, Thursz M, Evans A, Wright G, Tarff S, O'Grady J, Williams R, Shawcross DL, **Chokshi S**. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. *Gastroenterology.* 2015 Mar;148(3):590-602.e10.
  10. Della Peruta M, Badar A, Rosales C, **Chokshi S**, Kia A, Nathwani D, Galante E, Yan R, Arstad E, Davidoff AM, Williams R, Lythgoe MF, Nathwani AC. Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. *Hum Gene Ther.* 2015 Feb;26(2):94-103.
  11. **Chokshi S** & Phillips S, Chatterji, Riva A, Bobardt M, Williams R, Gallay P, Naoumov NV. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. *Gastroenterology.* 2015 Feb;148(2):403-14.e7.
  12. **Chokshi S**, Cooksley H, Riva A, Phillips S, Williams R, Gaggar A, Naoumov NV.

Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption. *Viral Immunol.* 2014 Jun;27(5):235-44.

13. Riva A, Laird M, Casrouge A, Ambrozaitis A, Williams R, Naoumov NV, Albert ML, **Chokshi S.** Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. *Hepatology.* 2014 Aug;60(2):487-96.